BRAFV600E and KIT immunoexpression in early-stage melanoma

Area of Science:

• Oncology
• Dermatology
• Molecular Pathology

Background:

• Melanoma is the deadliest skin cancer, with early diagnosis significantly improving survival rates.
• Identifying reliable biomarkers for early-stage melanoma is a critical challenge for clinicians and researchers.
• The mitogen-activated protein kinase (MAPK) pathway is frequently implicated in melanoma development.

Purpose of the Study:

• To evaluate the immunoexpression of BRAFV600E and KIT proteins in a cohort of early-stage melanomas.
• To investigate the concordance of BRAFV600E and KIT expression in thin invasive melanomas.
• To contribute to the understanding of molecular alterations in early melanoma development.

Main Methods:

• A case series of 44 early-stage melanomas was analyzed.
• Immunohistochemistry was employed to assess BRAFV600E and KIT protein expression.
• Samples were evaluated using a semi-quantitative scoring system based on percentage and intensity of immunostained tumor cells.

Main Results:

• Significant concordance was observed between BRAFV600E and KIT immunoexpression in thin invasive melanomas.
• The findings support the role of abnormal protein expression within the MAPK signaling pathway in early melanoma.
• This study provides quantitative data on specific protein markers in early disease stages.

Conclusions:

• BRAFV600E and KIT immunoexpression are concordant in early-stage, thin invasive melanomas.
• These proteins may serve as potential biomarkers for early melanoma detection and prognostication.
• The study reinforces the involvement of MAPK pathway dysregulation in the initial phases of melanoma.